Lupin Ltd, a major pharmaceutical manufacturer, reported a 16% increase in consolidated net profit after tax, reaching ₹1,416.98 crore in the first quarter ending June 30, driven by steady growth in key markets.
The company stated in regulatory filings on Thursday that the consolidated profit after tax for the same period last fiscal year was ₹1,221.46 crore. For the reporting quarter, total operating revenue reached ₹8,276.89 crore compared to ₹6,268.34 crore the previous year.
Meanwhile, total expenses in the quarter under review increased to ₹6,389.83 crore, up from ₹4,931.84 crore in the corresponding period last fiscal year.
Management Commentary
Commenting on the results, Lupin Ltd Managing Director Nilesh Gupta expressed satisfaction with the strong start to fiscal year 2027, noting that the growth is attributed to robust development in core markets and continuous improvement in profitability. He added that the company's focus on execution, operational excellence, and ongoing investment in technology and innovation strengthens the business and ensures sustainable, profitable growth in the long term.
In the first quarter, sales in the US market amounted to ₹3,434.8 crore, which is 42.9% higher than ₹2,404.1 crore in the same period last year. Sales in India grew by 13.9% to reach ₹2,379.6 crore compared to ₹2,089.4 crore the previous year. Furthermore, sales in other developed markets totaled ₹1,149.4 crore versus ₹774.8 crore in the first quarter of the previous fiscal year, demonstrating a growth of 48.3%.



